Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Cabozantinib Bests Placebo in Extrapancreatic NETs With Primary Tumor Arising in the Gl Tract

January 24th 2025

A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

January 23rd 2025

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

January 22nd 2025

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer

January 21st 2025

E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.

ACS Annual Report Shows Cancer Incidence Rates Are Rising in Select Populations

January 21st 2025

The 2025 American Cancer Society Annual Report Showed incidence rates are increasing for many cancer types and disparities remain regarding cancer mortality.

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

January 21st 2025

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

January 16th 2025

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers

January 15th 2025

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.

Durvalumab Shifts Decades-Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC

January 15th 2025

Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.

Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations

January 14th 2025

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Genetic Testing Considerations and Questions Persist Surrounding Tumor-Agnostic Approvals

January 14th 2025

Pedro Barata, MD, details factors affecting treatment selection with biomarker-based approvals and highlights questions regarding genetic testing.

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

January 12th 2025

Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

January 10th 2025

Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

January 9th 2025

Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.

FDA Releases Draft Guidance on Tissue Biopsies in Clinical Trials

January 8th 2025

The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.

Retifanlimab Emerges as Potential New SOC in Advanced SCAC

January 7th 2025

Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

January 7th 2025

Nirav N. Shah, MD, MSHP, details how BTK degraders could fill an unmet need in pretreated CLL/SLL and highlights promising data seen with NX-5948.

One Surgeon’s Spirit and Brilliance Lift a Whole Community

January 3rd 2025

A childhood dream became a reality for Montana native Kelly K. Hunt, MD, FACS, FSSO, who has changed the face of the surgical breast oncology workforce.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer

December 26th 2024

Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.